A comparison of platelet function tests and thromboxane metabolites to evaluate residual platelet reactivity in patients with type 2 diabetes Original article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Dec 31, 2012
Keywords:
acetylsalicylic acid, platelet reactivity, thromboxane, diabetes mellitus

Main Article Content

Marek Postuła
Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej, Warszawski Uniwersytet Medyczny
Marek Rosiak
Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny
Agnieszka Kapłon-Cieślicka
Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny
Ewa Trzepla
I Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny
Krzysztof J. Filipiak
I Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny
Andrzej Członkowski
Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej, Warszawski Uniwersytet Medyczny
Grzegorz Opolski
I Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny

Abstract

Background: Type 2 diabetes (T2DM) patients are at increased risk of cardiovascular events despite long-term acetylsalicylic acid (ASA) therapy. We aimed to compare the results obtained from two major platelet function point-of-care tests and thromboxane A2 metabolites in the assessment of the prevalence of high platelet reactivity (HPR) on ASA in T2DM patients.


Methods and results: The study cohort consisted of 262 T2DM patients who had been taking ASA tablets at the dose of 75 mg per day for at least 3 months for primary or secondary prevention of myocardial infarction. Platelet reactivity analyzes were performed using VerifyNow Aspirin and PFA-100 assays. Thromboxane A2 metabolites were also measured in serum and urine to assess cyclooxygenase-1 specific platelet reactivity inhibition. The prevalence of HPR varied according to the assay used: 35,4%, for PFA-100 using epinephrine as the agonist, 16,1%, for VerifyNow Aspirin Assay, and finally, 21,6% by measuring urinary 11-dehydro-thromboxane B2 and 9,8% measuring serum throboxane B2 concentrations. HPR were found in over 55% of patients based on at least one test, and in only 2,2% based on all performed tests. Results from these tests showed poor correlation and agreement among themselves.


Conclusion: Platelet function tests are not equally effective in measuring HPR and correlate poorly among themselves.

Downloads

Download data is not yet available.

Article Details

How to Cite
Postuła , M., Rosiak , M., Kapłon-Cieślicka , A., Trzepla , E., Filipiak , K. J., Członkowski , A., & Opolski , G. (2012). A comparison of platelet function tests and thromboxane metabolites to evaluate residual platelet reactivity in patients with type 2 diabetes. Cardiology in Practice, 6(2), 10-18. Retrieved from https://www.journalsmededu.pl/index.php/kwp/article/view/1580
Issue
Vol 6 No 2 (2012)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Beckman J.A., Creager M.A., Libby P.: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-2581.
2. Yazbek N., Bapat A., Kleiman N.: Platelet abnormalities in diabetes mellitus. Coron. Artery Dis. 2003; 14: 365-71.
3. Natarajan A., Zaman A.G., Marshall S.M.: Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab. Vasc. Dis. Res. 2008; 5: 138-44.
4. Ferroni P., Basili S., Falco A., Davi G.: Platelet activation in type 2 diabetes mellitus. J. Thromb. Haemost. 2004; 2: 1282-91.
5. DiChiara J., Bliden K.P., Tantry U.S. et al.: The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 2007; 56: 3014-9.
6. Evangelista V., de Berardis G., Totani L. et al.: Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin. J. Thromb. Haemost. 2007; 5: 2197-203.
7. Mortensen S.B., Larsen S.B., Grove E.L., Kristensen S.D., Hvas A.M.: Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thrombosis Res. 2010; 126: 318-22.
8. Ertugrul D.T., Tutal E., Yildiz M. et al.: Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2010; 95: 2897-901.
9. Fateh-Moghadam S., Plockinger U., Cabeza N. et al.: Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol. 2005; 42: 99-103.
10. Yazbek N., Bapat A., Kleiman N.: Platelet abnormalities in diabetes mellitus. Coron. Artery Dis. 2003; 14: 365-71.
11. Takahashi S., Ushida M., Komine R. et al.: Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thrombosis Res. 2007; 119(4): 517-24.
12. Frelinger A.L. 3rd, Furman M.I., Linden M.D. et al.: Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113: 2888-96.
13. Blais N., Pharand C., Lordkipanidze M., Sia Y.K., Merhi Y., Diodati J.G.: Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb. Haemost. 2009; 102: 404-11.
14. Frelinger A.L., Li Y., Linden M.D. et al.: Aspirin ‘resistance’: role of pre-existent platelet reactivity and correlation between tests. J. Thromb. Haemost. 2008; 6: 2035-44.
15. Gremmel T., Steiner S., Seidinger D., Koppensteiner R., Panzer S., Kopp C.W.: Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. Platelets 2011; 22: 188-95.
16. Grove E.L., Hvas A.M., Johnsen H.L. et al.: A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb. Haemost. 2010; 103: 1245-53.
17. Gurbel P.A., Bliden K.P., DiChiara J. et al.: Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-64.
18. Harrison P., Segal H., Blasbery K., Furtado C., Silver L., Rothwell P.M.: Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005; 36: 1001-5.
19. Lordkipanidze M., Pharand C., Schampaert E., Turgeon J., Palisaitis D.A., Diodati J.G.: A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur. Heart J. 2007; 28: 1702-8.
20. Davi G., Catalano I., Averna M. et al.: Thromboxane biosynthesis and platelet function in type II diabetes mellitus. NEJM 1990; 322: 1769-74.
21. Postula M., Kaplon-Cieslicka A., Rosiak M. et al.: Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes. J. Thromb. Haemost. 2011; 9: 2291-301.
22. Crescente M., Di Castelnuovo A., Iacoviello L., Vermylen J., Cerletti C., de Gaetano G.: Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb. Haemost. 2008; 99: 14-26.
23. Christie D.J., Kottke-Marchant K., Gorman R.T.: Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. Platelets 2008; 19: 104-10.
24. Nielsen H.L., Kristensen S.D., Thygesen S.S., Mortensen J., Pedersen S.B., Grove E.L., Hvas A.M.: Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thromb. Res. 2008; 123: 267-73.
25. Capodanno D., Patel A., Dharmashankar K. et al.: Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ. Cardiovasc. Interv. 2011; 4: 180-7.
26. Angiolillo D.J., Shoemaker S.B., Desai B. et al.: Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007; 115: 708-16.
27. Harrison P., Frelinger A.L. 3rd, Furman M.I., Michelson A.D.: Measuring antiplatelet drug effects in the laboratory. Thromb. Res. 2007; 120: 323-36.
28. Yassine H.N., Davis-Gorman G., Stump C.S., Thomson S.S., Peterson J., McDonagh P.F.: Clinical determinants of aspirin resistance in diabetes. Diabetes Res. Clin. Pract. 2010; 90: e19-21.
29. Tantry U.S., Mahla E., Gurbel P.A.: Aspirin resistance. Prog. Cardiovasc. Dis. 2009; 52: 141-52.
30. Maree A.O., Curtin R.J., Dooley M., Conroy R.M., Crean P., Cox D., Fitzgerald D.J.: Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J. Am. Coll. Cardiol. 2005; 46: 1258-63.
31. Catella F., Healy D., Lawson J.A., Fitzgerald G.A.: 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proceedings of the National Academy of Sciences of the United States of America 1986; 83: 5861-5.
32. Patrignani P.: Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb. Res. 2003; 110: 281-6.
33. Ferreira I.A., Mocking A.I., Feijge M.A. et al.: Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 417-22.
34. Michelson A.D.: Methods for the measurement of platelet function. Am. J. Card. 2009; 103: 20A-6A.